Estradiol Valerate

HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk of cryptogenic ischaemic stroke (CIS) in young women.(1) The findings add to a growing body of evidence linking hormonal contraception to vascular risk in women of reproductive age. Cryptogenic ischaemic stroke, which is stroke with no identifiable cause, accounts for up to 40% of all ischaemic strokes in young adults.(2) Despite its prevalence, the contribution of sex-specific risk factors, such as contraceptive use, has remained underexplored. While prior studies have associated combined OCs with stroke risk, this is among the few studies to focus specifically on cryptogenic stroke in young women. The Searching for Explanations for Cryptogenic Stroke in the Young (SECRETO) study included 268 women aged 18–49 years with CIS and 268 age-matched stroke-free controls across 14 centres in Europe. Of the participants, 66 patients and 38 controls were using combined OCs. After adjusting for age and established comorbidities such as hypertension, smoking, migraine with aura, and abdominal obesity, OC use was associated with an adjusted odds ratio of 3.00 (95% CI: 1.61–5.57). No significant interactions were found between OC use and these risk factors, suggesting that the increased stroke risk may operate independently of other known contributors. "Our findings confirm earlier evidence linking oral contraceptives to stroke risk," said Dr. Mine Sezgin, Department of Neurology, Istanbul University, and lead author of the study. "What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological." Most OC users in the study were taking ethinylestradiol-based formulations, with a median dose of 20 micrograms. Other types of estrogen, such as estradiol hemihydrate and estradiol valerate, were also recorded. "We calculated the equivalent estrogen dose for each patient to ensure consistency," Dr Sezgin explained. "While our data provides important initial insights, larger studies are needed to determine if certain formulations carry different levels of risk. This knowledge could help guide more personalised contraceptive choices for women." While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing combined OCs to women with known vascular risk factors or a history of ischaemic stroke. "Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors," concluded Dr. Sezgin. Moving forward, the researchers plan to explore biological and genetic mechanisms underlying the observed association between combined OC use and increased stroke risk to better understand how hormonal contraceptives may independently elevate stroke risk. Note to editors: A reference to ESOC 2025 must be included in all coverage and/or articles associated with this study. About the study author: Dr. Mine Sezgin is a neurologist and stroke researcher based at the Istanbul University Faculty of Medicine. Her work focuses on sex-specific risk factors and stroke prevention in young adults. About the European Stroke Organisation (ESO): The ESO is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007. The aim of the ESO is to reduce the burden of stroke by changing the way that stroke is viewed and treated. This can only be achieved by professional and public education, and by making institutional changes. ESO serves as the voice of stroke in Europe, harmonising stroke management across the whole of Europe and taking action to reduce the burden of stroke regionally and globally. References: 1. Sezgin, M., et al. Hormonal contraception increases the risk of cryptogenic stroke in young women. Abstract O049, presented at the European Stroke Organisation Conference; 21 May 2025; Vienna, Austria. 2. Yaghi, S., & Elkind, M. S. (2014). Cryptogenic stroke: A diagnostic challenge. Neurology. Clinical practice, 4(5), 386–393. SOURCE European Stroke Organisation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

精彩内容近日，人福医药公告称，其全资子公司武汉普克申报的3类仿制药萘普生钠软胶囊（0.22g）国内首家获批生产并视同过评，截至目前累计研发投入约170万元。该产品属于非甾体类抗炎药物，米内网数据显示，2023年中国三大终端六大市场（统计范围详见本文末）抗炎抗风湿化药销售额超过220亿元。萘普生钠软胶囊为非甾体类抗炎药物，具有解热、镇痛、抗炎等作用，适用于缓解轻至中度疼痛，如关节痛、神经痛、肌肉痛、偏头痛、头痛、痛经、牙痛等。此前，萘普生钠有片剂、胶囊剂、颗粒剂、注射剂等多种剂型在销，此次人福医药的萘普生钠软胶囊剂国内首家获批，填补了该剂型的空白。值得一提的是，目前国内暂无企业布局该产品，人福医药有望在长时间内保持独家身份。米内网数据显示，2023年中国三大终端六大市场抗炎抗风湿化药销售额超过220亿元，同比增长约7%，2024上半年其销售额超过110亿元。从小类看，非甾体抗炎和抗风湿药占主导地位。近年来中国三大终端六大市场抗炎抗风湿化药销售情况（单位：万元）来源：米内网格局数据库2024上半年抗炎抗风湿化药TOP5品牌中，先声药业的1类新药艾拉莫德片居于榜首，较2023年提升1个位次；上药中西制药的硫酸羟氯喹片紧接其后，强生的布洛芬混悬液排位第三。从销售额增速看，江苏正大清江制药的盐酸氨基葡萄糖片大涨48.13%，先声药业的艾拉莫德片涨幅接近30%。2024上半年中国三大终端六大市场抗炎抗风湿化药TOP5品牌来源：米内网格局数据库今年以来，人福医药有8个品种获批生产并视同过评，包括5个神经系统药物、1个抗肿瘤和免疫调节剂、1个全身用抗感染药物及1个肌肉-骨骼系统药物。其中，萘普生钠软胶囊、盐酸他喷他多片为国内首仿+首家过评，琥珀酸地文拉法辛缓释片、马来酸咪达唑仑片国产第2家获批等。2025年以来人福医药获批上市的品种来源：米内网中国申报进度（MED）数据库此外，今年以来，人福医药还有5个品种以新注册分类申报上市/临床，分别为布瑞哌唑片（暂无首仿）、血管紧张素Ⅱ注射液（市场空白）、磷酸奥司他韦干混悬剂、戊酸雌二醇片及布洛芬软胶囊。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至4月25日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦